Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key Updates from ASH 2024: Patient Preferences and Shared Decision Making in Hematologic Cancers : Episode 1
Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024
Sikander Ailawadhi, MD, discusses how emerging trends in targeted therapies, immunotherapies, and precision medicine presented at ASH 2024 are addressing unmet needs in the management of hematologic cancers and shaping future treatment strategies.
Now Viewing
EP: 1.Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024
EP: 2.Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making
EP: 3.Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences
EP: 4.Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
EP: 5.Advancing Hematologic Care and the Future of Shared Decision-Making
Video content above is prompted by the following:
- Coming into ASH 2024, what would you consider to be the largest unmet needs in the management of hematologic cancers?
- What are the latest trends and innovations you have observed in the treatment and management of hematologic cancers leading up to and coming out of ASH 2024?
Related Videos
Related Content
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
November 26th 2025Article
The analysis found that zanubrutinib provides similar progression-free survival to fixed-duration venetoclax plus ibrutinib but with consistently fewer serious side effects, suggesting a more favorable overall safety profile.
Read More
